



March 4<sup>th</sup>, 2026

## Acuitas Therapeutics Named Top 100 Global Innovator by LexisNexis for 2026

**Vancouver, B.C.** – Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, today announced that it has been named a Top 100 Global Innovator in LexisNexis’s Innovation Momentum 2026 report for the fourth year in a row. This award highlights Acuitas’s continuous leadership in LNP innovation and the strength of its patent portfolio, underscoring its role in advancing next generation therapeutics.

“Being recognized for the fourth consecutive year reflects the ongoing dedication of our team and the strength of our science,” said Tom Madden, CEO of Acuitas Therapeutics. “Our continual innovation in LNP delivery is designed with a singular purpose in mind - to enable our partners to expand the clinical opportunities for nucleic acid therapeutics. When we advance delivery technology, we empower our collaborators to move promising medicines to patients in need.”

LexisNexis “Top 100 Global Innovators” list recognizes 100 companies around the world that are driving innovation across their businesses and their industries, based on the quality of their patent portfolios over a two-year period. Learn more about this award [here](#).

### About Acuitas Therapeutics

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas’ clinically validated LNP technology has had a profound global impact — most notably enabling the Pfizer-BioNTech COVID-19 vaccine, **COMIRNATY®**, which has protected billions of people in more than 180 countries. Its technology also enables **ONPATTRO®** by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas’ LNP technology has delivered other groundbreaking firsts: the **first in-human proof of concept** for genome base editing and the **first personalized CRISPR therapy**.

Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and *in vivo* CAR T-cell therapies, epigenetic medicines to modulate gene expression without altering DNA, and multivalent vaccines for



infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.

For more information, visit [www.acuitastx.com](http://www.acuitastx.com).

-END-